Interleukin 15 (IL-15) is one of the most important cytokines that regulate the biology of natural killer (NK) cells 1 . Here we identified a signaling pathway-involving the serine-threonine kinase AKT and the transcription factor XBP1s, which regulates unfolded protein response genes 2,3 -that was activated in response to IL-15 in human NK cells. IL-15 induced the phosphorylation of AKT, which led to the deubiquitination, increased stability and nuclear accumulation of XBP1s protein. XBP1s bound to and recruited the transcription factor T-BET to the gene encoding granzyme B, leading to increased transcription. XBP1s positively regulated the cytolytic activity of NK cells against leukemia cells and was also required for IL-15-mediated NK cell survival through an anti-apoptotic mechanism. Thus, the newly identified IL-15-AKT-XBP1s signaling pathway contributes to enhanced effector functions and survival of human NK cells.
In addition, the expression of transcripts for XBP1s target genes, including ERDJ4 and SEC61A1 (ref. 9 ), was significantly increased in IL-15-treated primary human NK cells compared with that of untreated, IL-2-treated or IL-12-treated cells (Fig. 1c ).
We next investigated the effects of XBP1s overexpression on NK cell function. Primary human NK cells transfected with pCDH lentivirus carrying a wild-type XBP1s gene (pCDH-XBP1s) and co-cultured with K562, MOML13 or U937 leukemia cell lines had a higher percentage of CD107a + NK cells than that of NK cells transfected with the lentivirus carrying an empty pCDH vector (pCDH-EV) ( Fig. 1d ). Upon co-culture with MOML13 target cells, the percentage of CD107a + cells in primary human NK cells transduced with pLKO.1 lentivirus carrying XBP1-specific short hairpin RNAs (shRNAs) (XBP1-knockdown (XBP1-KD)) was significantly decreased (an approximately 35% reduction) compared with cells transduced with pLKO.1 lentivirus carrying scrambled shRNAs (scramble-KD) (Fig. 1e ). In addition, primary human NK cell degranulation against multiple myeloma MM.1S cells was observed in IL-15-treated but not in untreated primary human NK cells ( Fig. 1f ). When co-cultured with MM.1S multiple myeloma cells, the percentage of CD107a + NK cells expressing XBP1s was approximately fourfold greater than that of CD107a + NK cells lacking XBP1s ( Fig. 1f ). Moreover, the expression of XBP1s protein was significantly higher in CD107a + than in CD107a ─ primary human NK cells co-cultured with MM.1S cells ( Supplementary Fig. 1b ), indicating that expression of XBP1s correlates with NK cell cytotoxicity against tumor cells. Collectively, our results suggest that IL-15 induces XBP1s protein expression and that the expression level of the transcriptional factor directly correlates with cytotoxic activity in human NK cells.
To investigate how XBP1s regulates NK cell function, we analyzed the expression of genes encoding molecules related to NK cell effector functions, including GZMB (granzyme B), IFNG (interferon-γ ), and PRF1 (perforin). Expression of GZMB and IFNG mRNA, but not that of PRF1 mRNA, was higher in pCDH-XBP1s-transduced primary human NK cells compared with pCDH-EV-transduced control NK cells ( Fig. 2a (Fig. 2b,c) . Overexpression of the unspliced form of XBP1, XBP1u-which can be processed into XBP1s through IRE1α -mediated mRNA splicing-in primary human NK cells by transduction with pCDH lentivirus carrying a wild-type XBP1u gene (pCDH-XBP1u) also increased the expression of GZMB compared with pCDH-EV NK cells (Fig. 2b,c) . Moreover, primary human NK cells treated with thapsigargin, a chemical drug that induces endoplasmic reticulum stress and IRE1α catalytic activity 10 , increased XBP1s protein and GZMB mRNA and protein compared with NK cells without thapsigargin treatment, in the absence or presence of IL-15 ( Supplementary Fig. 2a-c ). In addition, downregulation of GZMB protein expression was observed in primary human NK cells transfected with XBP1-specific small interfering RNAs (siRNAs) compared with cells transfected with scrambled control siRNAs ( Supplementary Fig. 2d,e ). We also observed decreased expression of both GZMB and IFNG, but not of PRF1, in primary human NK cells with XBP1-KD using shRNA, compared with scramble-KD control NK cells ( Fig. 2d ). Inhibition of XBP1 mRNA splicing in primary human NK cells with 4µ 8C, an inhibitor of IRE1α -mediated mRNA splicing 11 , resulted in decreased expression of XBP1s protein and suppression of IL-15-induced GZMB protein and mRNA compared with cells not treated with 4µ 8C ( Supplementary Fig. 2f -h). The expression of XBP1s protein was positively correlated with the mRNA expression of GZMB and IFNG, all of which were induced by treatment with IL-15 at multiple time points in primary human NK cells ( Fig. 2e ). Thus, XBP1s positively regulates the expression of GZMB and interferon-γ in NK cells.
We next investigated the cellular localization of XBP1s. Immunoblot analysis of the cytoplasmic and nuclear protein fractions in primary human NK cells treated with IL-15 for 24 h indicated that XBP1s exists almost exclusively in the nucleus following induction by IL-15 ( Fig. 3a) , consistent with its role in regulating transcription 12 . Next, we overexpressed T-BET and FLAG-XBP1u or FLAG-XBP1s in 293T cells. Co-immunoprecipitation followed 
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by immunoblot using antibodies to FLAG or T-BET indicated that overexpressed FLAG-XBP1s interacted with T-BET (Fig. 3b ,c and Supplementary Fig. 3a ), a transcriptional regulator important for NK cell function. T-BET was previously assumed to associate with the GZMB promoter, although no specific binding sites have been identified 13, 14 . Of note, in 293T cells FLAG-XBP1s did not interact with endogenous STAT5, an important transcriptional factor downstream of IL-15 signaling ( Fig. 3c ). Using confocal imaging with antibodies that identify both XBP1u and XBP1s, and a T-BET antibody, we observed the co-localization of T-BET and XBP1 in the nuclei of primary human NK cells ( Fig. 3d ) and in the human NK cell lymphoma cell line NK-92 ( Supplementary Fig. 3b ). Confocal microscopy indicated that T-BET has an almost exclusively nuclear distribution in NK cells ( Fig. 3d ), which was validated by staining with an alternative antibody to T-BET in both primary NK cells and NK-92 cells ( Supplementary Fig. 3c ). Next, we tested whether XBP1s interacted with its canonical binding motifs (G/C)ACGT 15, 16 located within the GZMB proximal promoter ( Fig. 3e ). Chromatin immunoprecipitation (ChIP) indicated that XBP1s and T-BET bound to the same proximal region of the GZMB promoter in primary human NK cells treated with IL-15, but there was little or no binding in untreated cells ( Fig. 3e,f) . In contrast, T-BET did not bind to the GZMB promoter in primary human NK cells treated with 4µ 8C (which do not express XBP1s; Supplementary Fig. 2g ) in the presence of IL-15, compared with control cells treated with only IL-15 ( Supplementary Fig. 3d ). Using a luciferase assay to evaluate GZMB promoter activity, we observed that 293T cells transfected with XBP1s had much higher GZMB promoter activity than that of the cells transfected with EV ( Fig. 3g ). Of note, we also observed STAT5 binding to the GZMB promoter in primary human NK cells by ChIP assays (Fig. 3e ), consistent with previous reports 17 . STAT5 positively regulates GZMB expression [17] [18] [19] ; however, STAT5 did not interact with FLAG-XBP1s in 293T cells, as determined by co-immunoprecipitation assays ( Fig. 3c ). To test whether STAT5 was required for GZMB induction by XBP1s, we knocked down the expression of STAT5A or STAT5B using shRNAs in 293T cells that were co-transfected with pCDH-XBP1s or pCDH-EV and a pGL3 vector carrying the GZMB promoter reporter (pGL3-GZMB) ( Supplementary Fig. 4a ). The induction of the GZMB promoter reporter by XBP1s overexpression was not inhibited by either STAT5A-KD (279%) or STAT5B-KD (184%) in 293T cells compared with control 293T cells (175%) ( Supplementary Fig. 4b ), indicating that induction of GZMB promoter activity by XBP1s and T-BET in 293T cells does not require STAT5. Together, our data suggest that XBP1s interacts with T-BET but not STAT5 and regulates the transcriptional activity of GZMB via promoter binding.
XBP1 encodes a survival molecule that protects cells from stressinduced death 20, 21 , and IL-15 is a critical cytokine for NK cell survival 1, 22 . Knockdown of XBP1 by transfection with XBP1-specific XBP1s mRNA (relative)
Fig. 2 | XBP1s regulates GZMB and interferon-γ expression in NK cells. a, NK cells were transduced with an
XBP1s lentiviral construct or EV and, 48 h later, were FACS sorted for transduced GFP + cells, which were co-cultured with K562 cells for 4 h and then fractionated with anti-CD56 magnetic beads, followed by qPCR analysis. Bar graphs display mean ± s.e.m. of n = 3 donors. **P < 0.01, ***P < 0.001 by Student's two-tailed unpaired t-test. b, NK cells were transduced with XBP1u, XBP1s or pCDH-EV by lentiviral infection and cultured with IL-15 (100 units ml −1 ) for 48 h and then were FACS sorted for GFP + cells to determine XBP1s and GZMB protein expression by immunoblotting. The experiment was repeated three times with similar results. c, Densitometric quantification of the ratio of the level of XBP1s or GZMB protein to the level of β -actin protein for b. Bar graphs display mean ± s.d. of n = 3 donors. *P < 0.05 by linear mixed model. d, NK cells were transduced with an XBP1-specific or scrambled shRNA lentiviral construct (pLKO.1) and, 48 h later, were FACS sorted as in a. FACS-purified cells were co-cultured with K562 cells for 4 h and then fractionated with anti-CD56 magnetic beads, followed by qPCR analysis. Bar graphs display mean ± s.e.m. of n = 3 donors. *P < 0.05 by linear mixed model. e, NK cells were treated with IL-15 (100 units ml −1 ), followed by immunoblotting or qPCR analysis. Numbers below lanes indicate the expression of XBP1s for the lane above, normalized to the expression of β -actin. The experiment was repeated independently three times with similar results. NS, not significant. Blot images (b,e) were cropped, and the full scans are shown in the Supplementary Dataset.
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NATurE ImmuNoLogy siRNAs resulted in increased expression of cleaved caspase-3 in primary human NK cells compared with cells transfected with scrambled siRNAs (Fig. 4a ), indicating increased apoptosis in XBP1-KD NK cells. In contrast, primary human NK cells transduced with pCDH-XBP1u or pCDH-XBP1s showed decreased expression of cleaved caspase-3 compared with pCDH-EV control NK cells ( Fig. 4b ). Moreover, in IL-15-activated primary human NK cells in which XBP1 splicing was inhibited by treatment with 4µ 8C, cleaved caspase-3 levels were higher and survival was lower compared with similarly activated cells without 4µ 8C treatment ( Fig. 4c-f ). Taken together, these data indicate that XBP1s modulates IL-15-induced survival in human NK cells.
Next we investigated the molecular mechanism by which IL-15 regulated the expression of XBP1s protein. IL-15 stimulation of primary human NK cells did not increase the amount of XBP1s mRNA compared with unstimulated NK cells, as evaluated by XBP1 splicing assays and quantitative PCR (qPCR); however, XBP1s protein accumulated in the nucleus of IL-15-treated primary human NK cells within 2 h of stimulation ( Fig. 5a,b ). IL-15 stimulation also induced the phosphorylation of the serine-threonine kinase protein kinase B (PKB; also known as AKT) in NK cells mainly in the cytoplasm (Fig. 5b) , as previously reported 23 . Blockade of AKT phosphorylation with the AKT inhibitor AKTi-1/2 (ref. 24 ) in IL-15stimulated primary human NK cells resulted in decreased expression of XBP1s protein compared with cells treated with IL-15 in the absence of AKTi-1/2 ( Fig. 5c and Supplementary Fig. 5a ). Moreover, the expression of GZMB mRNA and GZMB protein was significantly downregulated in primary NK cells transduced with AKT1specific shRNA compared with scrambled shRNA ( Supplementary  Fig. 5b,c) . In addition, the expression of GZMB mRNA was significantly upregulated and GZMB protein was moderately upregulated in primary NK cells transduced with a constitutively active form of AKT (pCDH-myrAKT Δ4-129 , encoding a 14-amino acid Src myristoylation signal peptide fused to the N terminus of AKT Δ4-129 (ref. 25 )) compared with cells transduced with control pCDH-EV ( Supplementary Fig. 5d,e ). Treatment with AKTi-1/2 also reduced were fractionated from primary human NK cells, followed by immunoblot analysis. b, FLAG-XBP1s and T-BET were co-transfected into 293T cells, followed by immunoprecipitation and immunoblot analyses. c, T-BET-expressing 293T cells were transfected with FLAG-XBP1u, FLAG-XBP1s or the control (pCDH) vector, followed by immunoprecipitation and immunoblot analyses. d, NK cells were treated with IL-15 (100 units ml −1 ) for 24 h, followed by immunofluorescent staining with an anti-XBP1 that recognizes both XBP1u and XBP1s as well as anti-T-BET and anti-β -actin. The nuclei were stained by 4,6-diamidino-2-phenylindole (DAPI; blue). Yellow indicates overlay of green and red. e,f, NK cells were treated with IL-15 for 16 h, followed by ChIP assays performed with specific antibody or control IgG. Precipitated DNA was analyzed by PCR (e) or qPCR (f). Bar graphs display mean ± s.d. of n = 3 donors. *P < 0.05 by Student's two-tailed unpaired t-test. g, XBP1s or control vector was co-transduced with a pGL3 plasmid containing the GZMB promoter and a pRL-TK plasmid (as a control for data normalization) into 293T cells for 48 h. Cells were lysed to determine the promoter activity of GZMB by luciferase reporter assays. Bar graphs display mean ± s.e.m. of n = 4 independent experiments. ***P < 0.001 by Student's two-tailed unpaired t-test. The experiment was repeated independently two times (a,b) or three times (c,d,e) with similar results. Blot (a,b,c) and gel (e) images were cropped, and the full scans are shown in Supplementary Dataset.
NATurE ImmuNoLogy
the level of XBP1s protein in IL-15-stimulated NK cells in the presence of cycloheximide (CHX), which blocks de novo protein synthesis and thus prevents any confounding effects of increased protein translation 26 (Fig. 5d and Supplementary Fig. 6a ). These data indicate that AKT plays a role in increasing the IL-15-induced protein levels, but not mRNA expression, of XBP1s in primary human NK cells.
To further test whether AKT is required for maintaining the level of XBP1s protein, we co-transfected various concentrations of pECE-myrAKT Δ4-129 or pECE-EV with pCDH-FLAG-XBP1s or pCDH-EV into 293T cells. Immunoprecipitation experiments indicated that the level of FLAG-XBP1s protein was markedly increased in a dose-dependent manner by myrAKT Δ4-129 overexpression ( Fig. 5e and Supplementary Fig. 6b ), while XBP1s mRNA was not induced by overexpression of myrAKT Δ4-129 (Fig. 5f) , consistent with the idea that IL-15-induced XBP1s upregulation is independent of XBP1s transcription. In addition, co-transduction of pCDH-XBP1s and pECE-myrAKT Δ4-129 enhanced the activity of the GZMB promoter in 293T cells compared with transfection of pCDH-XBP1s alone ( Supplementary Fig. 6c ). These data indicate that AKT activation is required for maintaining the level of XBP1s protein.
Over time, during 4 h of incubation, a decrease was observed in FLAG-XBP1s protein in 293T cells transfected with pECE-EV but not in cells transfected with pECE-myrAKT Δ4-129 following CHX treatment ( Fig. 5g and Supplementary Fig. 6d ), suggesting that signaling downstream of AKT protects XBP1s from degradation. Blockade of proteosomal degradation with the cell-permeable proteasome and the calpain inhibitor MG132 27 recovered FLAG-XBP1s protein in pECE-EV-transfected but not pECE-myrAKT Δ4-129transfected 293T cells treated with CHX ( Fig. 5g and Supplementary  Fig. 6d ), indicating that overexpression of myrAKT Δ4-129 enhanced the protein stability of XBP1s in 293T cells. Ubiquitination of FLAG-XBP1s was reduced following transfection of pECE-myrAKT Δ4-129 compared with pECE-EV in 293T cells (Fig. 5h ), while ubiquitination of XBP1s was substantially increased in IL-15stimulated primary human NK cells treated with AKTi-1/2 compared with untreated cells (Fig. 5i ). Our data suggest that AKT controls XBP1s stability, possibly through a mechanism involving the ubiquitination of XBP1s.
Our studies describe a pathway that links IL-15 signaling with intracellular mechanisms that contribute to NK cell cytotoxicity and survival. We show that IL-15 stabilizes XBP1s protein through 
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However, there are no direct T-BET binding sites on the GZMB promoter 13, 14 . On the basis of the presence of an XBP1s binding motif within the GZMB promoter 13 , we showed that XBP1s mediates the interaction between T-BET and the GZMB promoter, as suggested by the ability of XBP1s to bind the promoter of GZMB and to interact with T-BET. We showed that AKT is involved in the regulation of XBP1s downstream of IL-15. Phosphatidylinositol-3-OH kinase (PI(3)K)-AKT signaling is stimulated by IL-2 and IL-15, with AKT phosphorylation being more sensitive to IL-15 than to IL-2 28 , in agreement with our data that IL-15 was the most potent cytokine (among IL-2, IL-12 and IL-15) in increasing XBP1s protein expression and function. AKT is known to regulate both protein ubiquitination and protein deubiquitination, with distinct mechanisms for each process 29, 30 . Ubiquitination and degradation of PTEN, a natural inhibitor of the PI(3)K-AKT pathway, in tumor cells require stabilization of the E3 ligase MKRN1 via AKT-mediated phosphorylation 30 . However, AKT also induces protein stabilization by activating USP-14, a ubiquitin-specific protease that handles the turnover of short-lived proteins via deubiquitination 29 . We showed here that AKT signaling caused the deubiquitination and promoted the accumulation of XBP1s. Consistent with our data, deficiency in either of the PI(3)K subunits p110γ or p110δ , which regulate AKT activity, has been reported to disrupt NK cell maturation, development ) for the indicated time period. c, NK cells were pretreated with or without AKTi-1/2 (10 µ M) for 30 min, followed by stimulation with IL-15 (100 units ml −1 ) for 6 h prior to immunoblotting. n = 3 donors. d, NK cells were pretreated with IL-15 (100 units ml −1 ) alone or plus AKTi-1/2 for 1 h, then cultured with or without CHX (10 µ g ml −1 ) for 30 min prior to immunoblotting. Data are summarized in Supplementary Fig. 6a . n = 3 donors. e, 293T cells were transfected with the indicated amount of pECE-myrAKT Δ4-129 vector and/or pCDH-FLAG-tagged XBP1s (FLAG-XBP1s) vector or respective control vector (dash) (1 µ g each) and cultured for 24 h. XBP1s protein was analyzed by immunoprecipitation with anti-FLAG, combined with immunoblotting. Data are summarized in Supplementary Fig. 6b . n = 3 independent experiments. f, XBP1s mRNA expression was analyzed by qPCR in pECE-myrAKT Δ4-129 -transfected or pECE control-transfected 293T cells co-transfected with pCDH-FLAG-XBP1s for 24 h (endogenous XBP1s is very low). Bar graphs display mean ± s.d. of n = 3 independent experiments. NS, not significant by Student's two-tailed unpaired t-test. g, 293T cells were co-transfected with pCDH-FLAG-XBP1s and pECE-myrAKT Δ4-129 or pECE-EV for 24 h and then treated with CHX (10 µ g ml −1 ) for the indicated time periods with or without MG132 (10 µ M). n = 3 independent experiments. h, myrAKT Δ4-129 or control (dash) was co-transfected with FLAG-XBP1s into 293T cells for 24 h with or without MG132 (10 µ M) for 4 h. Protein ubiquitination (Ub) of XBP1s was analyzed by immunoprecipitation with anti-FLAG, followed by immunoblotting with densitometric quantification. i, NK cells were pretreated with or without AKTi-1/2 (10 µ M) for 1 h followed by MG132 (10 µ M) treatment for 3 h in the presence of IL-15 (100 units ml −1 ). Ubiquitination of XBP1s was analyzed by immunoprecipitation with anti-ubiquitin combined with immunoblotting with anti-XBP1s. The experiment was repeated independently three times (b,h,i) with similar results. Gel (a) and blot images (b-e, g-i) were cropped, and the full scans are shown in the Supplementary Dataset.
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and cytotoxicity 31, 32 . Moreover, inhibition of PI(3)K suppresses GZMB expression in NK cells and decreases NK cell cytotoxicity against tumor cells [33] [34] [35] . These observations are consistent with our findings that IL-15 stimulation of NK cells caused an increase of AKT phosphorylation that correlated with decreased degradation of XBP1s, which subsequently enhanced NK cell degranulation following co-culture with tumor cells. Moreover, the active form of AKT, myrAKT Δ4-129 , enhanced the XBP1s-induced transcription of GZMB. Notably, myrAKT Δ4-129 alone slightly induced GZMB transcription in 293T cells, but a synergistic effect on GZMB transcription was observed following co-transfection with XBP1s.
IL-15 promotes NK cell survival 22 . However, the molecular basis of this mechanism remains poorly understood. Our current study supports a model in which XBP1s is located downstream of PI(3) K-AKT, and AKT contributes to the protein stability of XBP1s in NK cells following treatment with IL-15, eventually controlling NK cell survival. Consistent with our data, XBP1s is known to rescue cells from pro-apoptotic processes induced by endoplasmic reticulum stress, oxidative stress or hypoxia 20, 21, 36 . The anti-apoptotic protein Bcl-2 is highly expressed in resting NK cells 37 and contributes to NK cell survival in the resting state 38, 39 . However, Bcl-2 appears to be redundant for survival of activated or proliferating NK cells 38 .
Here we found that XBP1s was highly expressed in IL-15-activated NK cells, but its expression was relatively low in resting NK cells. Moreover, inhibition of XBP1s abolished the survival of IL-15activated NK cells but had no effect on the survival of resting NK cells. Thus, we speculate that Bcl-2 is responsible for the survival of resting NK cells, while XBP1s is responsible for the survival of IL-15-activated NK cells. In conclusion, we showed that XBP1s acts as an essential transcriptional factor downstream of IL-15 and AKT signaling in controlling two important aspects of NK cell biology: effector functions and survival. The IL-15-AKT-XBP1s axis may offer a potential target to improve the therapeutic efficacy of ex vivo-expanded NK cells and/or chimeric-antigen-receptormodified NK cells 40 for the treatment of various cancers.
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Methods Isolation of primary human NK cells. Leukocyte-enriched peripheral blood samples of human healthy donors were obtained from the American Red Cross. Primary NK cells were isolated using the MACSxpress NK Cell Isolation Kit (Miltenyi Biotec) and Erythrocyte Depletion Kit (Miltenyi Biotec). Enriched NK cells were approximately 99% pure, which was confirmed by flow cytometry using antibodies to CD3 and CD56 (BD Biosciences). Primary human NK cells were used for the experiments in this study unless otherwise indicated that the NK-92 cell line was used for specific experiments. The protocols for human specimen collection were approved by the institutional review boards of The Ohio State University.
Cell culture. The K562 and NK-92 cell lines were purchased from the American Type Culture Collection (ATCC). The U937, MM.1S and MOML13 cell lines were obtained from the laboratory of M.A.C. These cell lines and primary NK cells were cultured in RPMI 1640 medium containing l-glutamine (Sigma-Aldrich) and supplemented with 10% or 20% heat-inactivated FBS (Sigma-Aldrich). The 293T cell line, which was purchased from ATCC, was cultured in DMEM (Sigma-Aldrich) supplemented with 10% FBS. All cells were incubated at 37 °C in a humidified incubator containing 5% CO 2 .
Antibodies and other reagents. Antibodies to β -actin, lamin B, XBP1 and T-BET (immunoblotting, immunoprecipitation and immunofluorescence) were purchased from Santa Cruz Biotechnology. Antibodies to p-AKT (S473), AKT, α -tubulin, FLAG, p-STAT5, STAT5, GZMB, T-BET (ChIP and immunofluorescence), ubiquitin (for immunoblot), GAPDH and C-CASP3 were purchased from Cell Signaling Technology (CST). The monoclonal antibody to ubiquitin for immunoprecipitation was purchased from MilliporeSigma. Antibody to HA was purchased from Sigma-Aldrich. Antibody to XBP1s for immunoblot was purchased from BioLegend. Antibodies to hCD3-APC-H7 (catalog number 560176), hCD56-FITC (557699), hCD56-V450 (560360), hCD107a-APC (560664), hCD107a-APC-H7 (561343), XBP1s (563382) and hGZMB (560212) Transient transfection and lentivirus infection. The 293T cells were seeded and incubated at 37 °C in a 5% CO 2 environment until they were 60-80% confluent. The cells were transfected with plasmids using Lipofectamine 3000 Reagent (Thermo Fisher Scientific). NK cells were transfected with esiRNA (Sigma-Aldrich) using the nucleofection method (Lonza Bioscience) 41 . To generate lentivirus to infect human NK cells, 293T cells were co-transfected with pCDH expressing XBP1u, XBP1s or myrAKT Δ4-129 , with pLKO.1 expressing XBP1or AKT1-specific shRNA, or with corresponding control plasmids with the packaging constructs pCMV-VSVG and pCMV-Δ R9, by a ProFection Mammalian Transfection System (Promega). The protocols for virus production and infection were modified from our previous reports 42, 43 . During the lentiviral infection process, IL-15 was introduced into the cell culture to maintain survival of NK cells. Immunoblotting. Cells were suspended in lysis buffer on ice for 1 h. Equal amounts of protein (~20 μ g) were resolved by 5-20% SDS-polyacrylamide gels (Bio-Rad) and then transferred onto a PVDF membrane (Thermo Fisher Scientific). The membrane was incubated with a primary antibody at 4 °C for 16 h and a horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature 44,45 . The immunoblots were visualized with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific). Densitometric analysis was performed to quantify intensity of gel bands.
RT-PCR and
Immunoprecipitation. Cell lysates were prepared with NP40 lysis buffer. For 293T cells, cell lysates were prepared 48 h after plasmid transfection unless otherwise indicated. A beads-antibody complex was prepared using appropriate primary antibodies and Pierce Protein G Agarose (Thermo Fisher Scientific), followed by immunoprecipitation according to the manufacturer's protocol and as we have previously reported 43 . The precipitated proteins were detected by immunoblotting.
ChIP. ChIP assays were carried out with a Magna ChIP A/G Chromatin Immunoprecipitation Kit (EMD Millipore). Briefly, an equal amount (10 μ g) of rabbit anti-XBP1s antibody (BioLegend), rabbit anti-STAT5 antibody (CST), rabbit anti-T-BET antibody (CST) or normal immunoglobulin G (IgG; Santa Cruz Biotechnology) was used to precipitate the cross-linked DNA-protein complexes from 10 × 10 6 NK cells. After reversal of cross-linking, the precipitated chromatin of the GZMB promoter region was detected by PCR using the following primers: forward primer, GGGCTCAAACACATACCTGC; reverse primer, TGACCACATCATCACCCACAG.
Luciferase reporter assay. Luciferase reporter assays were carried out with a Dual-Luciferase Reporter Assay System (Promega), following our published protocol 46 with modifications. After 48 h transfection, cells on a 24-well plate were lysed in 100 µ l of 1X Passive Lysis Buffer (Promega). Lysates (20 µ l) were transferred to a 96-well plate, 100 µ l 1X Glo luciferase assay substrate (Promega) was added to each well, and firefly luciferase was collected from the transfected pGL3 plasmid using the GloMax 96 Microplate Luminometer (Promega). Renilla luciferase from the cotransfected pRL-TK plasmid (as a normalized control) was collected after injection with 100 µ l 1X Stop Substrate (Promega).
Flow cytometry. Cells were labeled with monoclonal antibodies at room temperature for 15 min and washed with PBS containing 2% BSA prior to analysis using an LSRII flow cytometer (BD Biosciences) to detect surface expression of each antigen. NK cells were gated as CD56 + CD3 ─ lymphocytes. For analysis by intracellular flow cytometry, cells were permeabilized and fixed using a Foxp3/Transcription Factor Fixation/Permeabilization Kit (eBioscience).
Statistical analysis.
For continuous, normally distributed data, two-sample t-tests or paired t-tests were used to compare two independent or two paired groups. A linear mixed model was used to compare three or more groups with a variancecovariance structure due to repeated measures from the same donors. A two-way analysis of variance (ANOVA) model was applied to the synergistic effect test between two factors. P values were adjusted for multiple comparisons using Holm's procedure. A P value of 0.05 or less was considered statistically significant.
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
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